Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) Equity Average: 2019-2025

Historic Equity Average for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $23.5 million.

  • Eton Pharmaceuticals' Equity Average rose 59.93% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 59.93%. This contributed to the annual value of $20.0 million for FY2024, which is 39.75% up from last year.
  • Eton Pharmaceuticals' Equity Average amounted to $23.5 million in Q3 2025, which was down 2.73% from $24.2 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Equity Average's 5-year high stood at $24.4 million during Q1 2025, with a 5-year trough of $12.1 million in Q4 2022.
  • Moreover, its 3-year median value for Equity Average was $16.2 million (2023), whereas its average is $17.8 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Equity Average soared by 332.31% in 2021, and later tumbled by 37.04% in 2022.
  • Eton Pharmaceuticals' Equity Average (Quarterly) stood at $16.6 million in 2021, then declined by 27.13% to $12.1 million in 2022, then spiked by 33.43% to $16.2 million in 2023, then grew by 24.84% to $20.2 million in 2024, then soared by 59.93% to $23.5 million in 2025.
  • Its Equity Average stands at $23.5 million for Q3 2025, versus $24.2 million for Q2 2025 and $24.4 million for Q1 2025.